Short answer
Liquidia Corp (LQDA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Liquidia announced third-quarter 2026 financial results for the period ended September 30, 2026.
Liquidia Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Liquidia announced third-quarter 2026 financial results for the period ended September 30, 2026
- Corporate update accompanies the results, with substantive details in Exhibit 99.1
Item 8.01 · Other Events
- Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
- Exhibit 99.2 contains the substantive investor-facing information and may affect market expectations
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 YUTREPIA sales reached $222.7 million, up 31% sequentially and sharply strengthening the commercial growth profile
- Global settlement resolved six United Therapeutics lawsuits, preserving YUTREPIA access but requiring $380.7 million in payments during 2026 and 2027
- PH-ILD label removal and halted promotion narrow YUTREPIA’s addressable market, creating potential revenue pressure despite uninterrupted patient treatment
- Net loss $236.3 million included a $389.7 million litigation charge, while adjusted EBITDA reached $140.5 million for the fifth consecutive quarter
- Cash rose to $396.1 million before settlement payments, supporting obligations but leaving total liabilities at $708.4 million versus $682.9 million of assets
Item EX-99.2 · Exhibit EX-99.2
- Q3 2026 net product sales $222.7M, up 31% sequentially, marking the fifth consecutive quarterly growth period
- YUTREPIA demand broadened to 1,300 prescribers, with over 60% generating at least two referrals
- Adjusted EBITDA $140.5M, up 46% sequentially, indicating substantial operating leverage from commercial scale
- GAAP net loss $236.3M, driven by a $389.7M United Therapeutics litigation-settlement charge
- Settlement supports continued YUTREPIA commercialization in PAH, while PH-ILD promotion and sales face label-related uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Liquidia Corp 8-K filings
Get the next LQDA 8-K as it lands
Follow LQDA for push alerts, or ask the research agent what this filing means.